| Panhandle Cataract And Laser Institute Llc | |
|
5101 N. Davis Hwy, Pensacola, FL 32503-2040 | |
| (850) 438-1277 | |
| (850) 438-1278 |
| Full Name | Panhandle Cataract And Laser Institute Llc |
|---|---|
| Type | Facility |
| Speciality | Specialist |
| Location | 5101 N. Davis Hwy, Pensacola, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245611268 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Secondary |
| 174400000X | Specialist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Panhandle Cataract And Laser Institute Llc 5101 N. Davis Hwy, Pensacola, FL 32503-2040 Ph: (850) 438-1277 | Panhandle Cataract And Laser Institute Llc 5101 N. Davis Hwy, Pensacola, FL 32503-2040 Ph: (850) 438-1277 |
News Archive
In a study that will be published in Nature Communications on May 28, 2021, a research team led by Dr. Yuan Liu from Georgia State University reports that intratumoral SIRPĪ±-deficient macrophages activate tumor antigen-specific cytotoxic T cells to eliminate various syngeneic cancers under radiotherapy.
Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the third fiscal quarter ended December 31, 2012.
The irony of getting away to a remote place is you usually have to fight traffic to get there. After hours of dodging dangerous drivers, you finally arrive at that quiet mountain retreat, stare at the gentle waters of a pristine lake, and congratulate your tired self on having "turned off your brain."
During Tuesday's oral arguments, the justices suggested that the state law, which restricts pharmaceutical marketers' ability to obtain data on doctor prescribing habits, may violate free-speech rights.
Chelsea Therapeutics International, Ltd. announced the completion and favorable outcome of an independent Data Monitoring Committee (DMC) review of the safety and efficacy data from approximately half the target enrollment in Chelsea's Phase II trial of droxidopa in fibromyalgia.
› Verified 3 days ago